India Approves First Indigenous mRNA Vaccine for Seasonal Flu
The Drug Controller General of India (DCGI) has granted emergency use authorization for the country's first indigenous mRNA vaccine for seasonal influenza.
2-Minute Summary (TL;DR)
- India's first indigenous mRNA vaccine for seasonal influenza received Emergency Use Authorization (EUA) from the DCGI on May 7, 2026.
- The vaccine was developed by a Pune-based pharmaceutical company in collaboration with the Department of Biotechnology (DBT).
- It utilizes messenger RNA (mRNA) technology, enabling faster production and easier adaptation to new viral strains.
- Phase III clinical trials demonstrated high efficacy (over 90%) and a favorable safety profile across various age groups.
- This development significantly reduces India's dependence on imported flu vaccines, bolstering self-reliance.
- The vaccine is planned for inclusion in national immunization programs, prioritizing high-risk groups.
- The indigenous mRNA platform enhances India's preparedness for future pandemics and public health emergencies.
- This milestone strengthens the 'Make in India' initiative and positions India as a leader in advanced vaccine technology.
How This Topic is Tested in Competitive Exams
| Exam | Frequency | Approx. Marks | What Gets Asked |
|---|---|---|---|
| SSC (CGL / CHSL / MTS) | High | 4–8 | Basic science, space missions, ISRO launches, and defence technology are standard SSC GK topics. |
| UPSC / State PCS | Medium | 5–8 | UPSC tests Science & Technology through governance: space policy, biotech regulations, cyber security. |
| Railway (RRB NTPC / Group D) | Very High | 6–10 | Science and Technology is one of the largest GK sections in Railway papers. |
| State PCS / PSC | Medium | 3–5 | Space missions, defence acquisitions, and health research appear regularly. |
Key Facts to Remember: India Approves First Indigenous mRNA Vaccine for Seasonal Flu
- India's first indigenous mRNA vaccine for seasonal influenza received Emergency Use Authorization (EUA) from the DCGI on May 7, 2026.
- The vaccine was developed by a Pune-based pharmaceutical company in collaboration with the Department of Biotechnology (DBT).
- It utilizes messenger RNA (mRNA) technology, enabling faster production and easier adaptation to new viral strains.
- Phase III clinical trials demonstrated high efficacy (over 90%) and a favorable safety profile across various age groups.
- This development significantly reduces India's dependence on imported flu vaccines, bolstering self-reliance.
- The vaccine is planned for inclusion in national immunization programs, prioritizing high-risk groups.
- The indigenous mRNA platform enhances India's preparedness for future pandemics and public health emergencies.
- This milestone strengthens the 'Make in India' initiative and positions India as a leader in advanced vaccine technology.
Practice Questions
Q1. What is the primary technology used in India's first indigenous mRNA vaccine for seasonal influenza?
- Viral Vector Technology
- Inactivated Virus Technology
- mRNA Technology
- Subunit Vaccine Technology
Explanation: The vaccine utilizes messenger RNA (mRNA) technology, which instructs the body's cells to produce specific proteins that trigger an immune response against the influenza virus. This is a key differentiator from traditional vaccine platforms.
Q2. Which regulatory body granted the Emergency Use Authorization (EUA) for India's indigenous mRNA flu vaccine?
- National Institute of Virology (NIV)
- Indian Council of Medical Research (ICMR)
- Central Drugs Standard Control Organization (CDSCO)
- Department of Biotechnology (DBT)
Explanation: The Drug Controller General of India (DCGI), which is part of the Central Drugs Standard Control Organization (CDSCO), is the regulatory authority responsible for granting approvals for drugs and vaccines in India.
Q3. The development of India's first indigenous mRNA seasonal flu vaccine was a collaborative effort between which two entities?
- A Pune-based pharmaceutical company and the Ministry of Health and Family Welfare
- The Serum Institute of India and the World Health Organization (WHO)
- A Pune-based pharmaceutical company and the Department of Biotechnology (DBT)
- Bharat Biotech and the National Institute of Allergy and Infectious Diseases (NIAID)
Explanation: The vaccine was developed through a partnership between a Pune-based pharmaceutical firm and the Department of Biotechnology (DBT), showcasing successful industry-academia-government collaboration.
Q4. What is a significant advantage of mRNA vaccine technology compared to traditional vaccine methods, as highlighted in the context of the new flu vaccine?
- Longer shelf life without refrigeration
- Lower cost of production per dose
- Faster development and easier adaptation to new viral strains
- Requires fewer clinical trial participants for approval
Explanation: mRNA vaccines can be designed and manufactured more rapidly than traditional vaccines. Furthermore, they can be quickly updated to match emerging or mutated strains of a virus, offering greater flexibility in response to evolving public health threats.
Q5. The approval of this indigenous mRNA flu vaccine is expected to primarily contribute to which of the following national goals?
- Increasing India's reliance on imported medical supplies
- Reducing the burden of seasonal influenza and enhancing pandemic preparedness
- Promoting traditional medicine over modern biotechnology
- Decreasing investment in domestic pharmaceutical research and development
Explanation: The development and approval of an indigenous vaccine significantly reduce India's dependence on imports, thereby strengthening national security and public health infrastructure. It directly aims to lower the impact of seasonal flu and bolster preparedness for future health crises.
How to Prepare Science & Technology for Government Exams — India Approves First Indigenous mRNA Vaccine for…
For Railway exams, make flashcards for every major ISRO launch — name, payload, purpose, date. These repeat frequently.
For SSC, focus on defence acquisitions and their strategic significance rather than technical specs.
For UPSC, connect every scientific development to policy — climate targets, digital India, health policy.
Related Current Affairs
Test Your Knowledge on Today's Current Affairs
10 questions · 10 minutes · Based on today's GK updates. See how prepared you really are.
Start Daily Quiz